Aethlon announces government research collaborations

Aethlon Medical, Inc. has announced that research related to the Aethlon Hemopurifier as a potential treatment for Ebola Hemorrhagic Fever has been initiated at The Centers for Disease Control and Prevention (CDC).

Written byLab Manager
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

Aethlon Medical, Inc. has announced that research related to the Aethlon Hemopurifier as a potential treatment for Ebola Hemorrhagic Fever has been initiated at The Centers for Disease Control and Prevention (CDC).

Ebola is classified as a category "A" bioterror threat presently untreatable with antiviral drug and vaccine therapy. According to the World Health Organization, Ebola causes death in 50-90 percent of all clinically ill cases.

Lab manager academy logo

Lab Management Certificate

The Lab Management certificate is more than training—it’s a professional advantage.

Gain critical skills and IACET-approved CEUs that make a measurable difference.

San Diego-based Aethlon Medical also said that the scope of these studies has been expanded to include researchers at The United States Army Medical Research Institute of Infectious Diseases (USAMRIID). USAMRIID is the lead medical research laboratory of the U.S. Biological Defense Research Program. The Institute plays a key role as the only laboratory in the Department of Defense equipped to study Ebola and other highly hazardous infectious agents requiring maximum containment at bio-safety level (BLS)-4.

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - May/June 2025

The Benefits, Business Case, And Planning Strategies Behind Lab Digitalization

Joining Processes And Software For a Streamlined, Quality-First Laboratory

Lab Manager May/June 2025 Cover Image